Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-288 in mild-to-moderate Alzheimer's disease
NCT01018875Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ABT-288 in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Dec 2009; status: completed.
02
Drugs
ABT-288
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01018875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01018875.